Rep. Roger Williams (R-TX) introduced HR 394 on May 6, 2025, a House Resolution expressing support for designating July 16, 2025 as Glioblastoma Awareness Day.
The measure is non-binding and serves as a formal endorsement from the House to elevate attention to glioblastoma and related research. Co-sponsors include Rep.
Mast, Rep. Schakowsky, and Rep.
Auchincloss.
The resolution frames the disease as a grave and ongoing health challenge, citing the annual diagnoses and mortality, the notably low survival rates, and the burden on patients and families. It also highlights the role of biomarker testing in diagnosis and treatment, and it points to research networks like the Glioblastoma Therapeutics Network as a pathway to accelerate progress.
Although aspirational, HR 394 does not create new funding or regulatory requirements. Instead, it urges increased public awareness, honors those affected, and calls for a collaborative, multi-sector approach to advancing glioblastoma research and treatment, including sustained investments in existing brain-tumor research resources.
At a Glance
What It Does
Designates July 16, 2025 as Glioblastoma Awareness Day and expresses support for increased public awareness and collaboration in glioblastoma research and treatment.
Who It Affects
Hospitals, cancer centers, patient advocacy groups, researchers, biotech and pharmaceutical communities, public health agencies, and individuals affected by glioblastoma and their families.
Why It Matters
Sets a formal, bipartisan acknowledgment of glioblastoma’s burden and promotes cooperative efforts across government, private, and nonprofit sectors to improve diagnosis, treatment, and research infrastructure.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill is a symbolic, non-binding expression of support from the House for designating a specific day to raise awareness about glioblastoma. It brings attention to the disease’s heavy burden—thousands diagnosed annually, thousands of deaths, and limited treatment success—while underscoring the importance of biomarker testing in guiding care.
The resolution also nods to existing research structures like the Glioblastoma Therapeutics Network and invites cross-sector collaboration to advance therapies and improve patient outcomes. Importantly, it does not authorize any new spending or create enforceable mandates; its primary purpose is awareness, recognition, and a call to action for researchers, clinicians, patient groups, and funders.
The bill’s sponsors and co-sponsors frame awareness as a precursor to broader support for research and treatment enhancements, aligning public attention with ongoing scientific efforts. Overall, HR 394 is a ceremonial step intended to catalyze attention and collaboration rather than to restructure policy or funding directly.
The Five Things You Need to Know
The resolution designates July 16, 2025 as Glioblastoma Awareness Day.
It urges increased public awareness and collaboration on glioblastoma.
It honors individuals affected by glioblastoma, including patients and families.
It calls for better treatments and emphasizes the role of biomarker testing.
It encourages continued investments in glioblastoma research, including through the Glioblastoma Therapeutics Network.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Designation of Glioblastoma Awareness Day
Designates July 16, 2025 as Glioblastoma Awareness Day and designates a focal point for observances and educational activities. The move is non-binding and serves as official congressional acknowledgment of the disease’s impact and the need for heightened visibility.
Public awareness and education
Calls for increased public awareness of glioblastoma, aiming to inform patients, caregivers, clinicians, and the general public about the disease, its diagnosis, treatment options, and ongoing research efforts. The provision signals a public-health framing rather than a regulatory mandate.
Biomarker testing and treatment considerations
Recognizes the importance of molecular biomarker testing in diagnosing glioblastoma and guiding therapy, framing testing as a critical component of appropriate care pathways and research enrollment decisions.
Collaboration and investment in research
Urges a collaborative approach among government, private sector, and nonprofit organizations to advance brain-tumor research. It highlights existing networks (such as GTN) as vehicles for accelerating discovery and clinical evaluation of new therapies.
Funding and enforcement caveat
Clarifies that the resolution does not authorize new funding or impose regulatory requirements. Its impact is aspirational and informational, designed to mobilize support and align stakeholders without creating enforceable obligations.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Glioblastoma patients and their families, who gain heightened visibility, potential access to new research directions, and a platform for advocacy.
- Brain-tumor researchers and the GTN network, which benefits from emphasized collaboration, awareness, and potential partnerships.
- Hospitals, cancer centers, and oncology departments, which can participate in observances and patient education without new regulatory burdens.
- Disease-advocacy organizations and patient communities, which receive a broader channel for outreach and fundraising support.
Who Bears the Cost
- Congressional and staff time devoted to organizing awareness activities and constituent engagement related to Glioblastoma Awareness Day.
- Public health agencies and healthcare institutions that may allocate resources for awareness events and educational materials (without new funding authorities).
- Nonprofit and patient-advocacy groups that may incur costs to organize campaigns and disseminate information.
- Media partners and educational institutions involved in public programming and outreach.
Key Issues
The Core Tension
The central dilemma is whether a symbolic, non-binding designation can meaningfully shift outcomes for glioblastoma patients without accompanying funding or policy changes, balancing awareness and collaboration against the risk of underutilizing the moment if not paired with concrete resource commitments.
The bill’s symbolism is its core value: it elevates glioblastoma in public discourse and reinforces cross-sector collaboration. Because it does not authorize expenditures or impose new rules, its practical impact rests on heightened awareness and the willingness of stakeholders to coordinate around shared objectives.
This is a potential strength—low fiscal risk and broad resonance—but it also means concrete policy outcomes depend on subsequent actions by agencies, researchers, and funders. A smart reader will ask how the awareness year translates into tangible improvements in diagnosis, access to testing, and treatment options, and whether allied policy efforts will accompany this recognition.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.